P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS

P988: MUTANT CALRETICULIN AND JAK2V617F DRIVER MUTATIONS INDUCE DISTINCT MITOTIC DEFECTS IN MYELOPROLIFERATIVE NEOPLASMS

Bibliographic Details
Main Authors:	Kristin Holl, Nicolas Chatain, Nathalie Brock, Susanne Krapp, Julian Baumeister, Steffen Koschmieder, Wolfram Antonin, Daniel Moreno-Andrés
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000970856.06181.5f

Similar Items

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
by: Kristin Holl, et al.
Published: (2024-02-01)

Mutant Calreticulin in the Myeloproliferative Neoplasms
by: Daniel Prins, et al.
Published: (2020-02-01)

The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling
by: Kathrin Olschok, et al.
Published: (2023-10-01)

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
by: Pecquet, C, et al.
Published: (2022)

P1008: THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING
by: Kathrin Olschok, et al.
Published: (2023-08-01)

Inflammation and anti-inflammatory approaches in myeloproliferative neoplasm
by: Steffen Koschmieder, et al.
Published: (2018-06-01)

Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms
by: Max Bermes, et al.
Published: (2023-12-01)

Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives
by: Julian Baumeister, et al.
Published: (2021-12-01)

Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms
by: Nicolas Chatain, et al.
Published: (2020-08-01)

P1001: MODULATION OF MUTANT CALRETICULIN-DRIVEN ONCOGENESIS IN MYELOPROLIFERATIVE NEOPLASMS BY CLASSICAL HLA GENES
by: Velizar Shivarov, et al.
Published: (2023-08-01)

The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia
by: Jingyi Wang, et al.
Published: (2016-08-01)

Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
by: Megumi Funakoshi-Tago, et al.
Published: (2013-01-01)

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
by: Panhong Gou, et al.
Published: (2024-01-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
by: İpek Yonal Hindilerden, et al.
Published: (2023-08-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
by: Saeid Shahrabi, et al.
Published: (2018-10-01)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
by: Sophie Allain-Maillet, et al.
Published: (2020-08-01)

The frequency of calreticulin and mpl gene mutations in bcr-abl and jak2 unmutated chronic myeloproliferative neoplasms and its effect on the outcome
by: T. Tiryaki, et al.
Published: (2020-10-01)

The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
by: Steffen Koschmieder
Published: (2021-06-01)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
by: W. Novak, et al.
Published: (2022-06-01)

The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
by: Lai Yee Orbell, et al.
Published: (2023-11-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
by: Alexandre Guy, et al.
Published: (2020-06-01)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
by: McKenney, Anna Sophia, et al.
Published: (2018)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.
by: Bench, A, et al.
Published: (2013)

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations
by: Bench, A, et al.
Published: (2013)

Concomitant BCR-ABL and JAK2 V617F in a patient with myeloproliferative neoplasm: a case report
by: A, Alia Suzana, et al.
Published: (2023)

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
by: Xuefei MA, et al.
Published: (2023-08-01)

Coexistence of JAK2V617F and CALR mutation in Tunisian cohort with Philadelphia-negative chronic myeloproliferative neoplasms
by: Hejer Elmahmoudi, et al.
Published: (2023-01-01)

Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms
by: Panhong Gou, et al.
Published: (2022-01-01)

P1009: SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION
by: Ailin Zhao, et al.
Published: (2023-08-01)

PB2040: INTERRELATION BETWEEN JAK2 V617F MUTATION AND THE INCIDENCE OF THROMBOTIC EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
by: D. Nikolova, et al.
Published: (2022-06-01)

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms
by: Charly Courdy, et al.
Published: (2023-07-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-04-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-06-01)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
by: Shivam Rai, et al.
Published: (2022-09-01)

Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms
by: Greenfield, G, et al.
Published: (2020)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
by: Graeme Greenfield, et al.
Published: (2020-09-01)

JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
by: Michael Stephan Bader, et al.
Published: (2022-01-01)

SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm
by: Yue Yang, et al.
Published: (2023-11-01)